Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vascanox HP is an encapsulated nutraceutical formulation developed by Calroy Health Sciences, designed to support cardiovascular health and blood pressure management. The product combines two key active components: S-allylcysteine (SAC), a sulfur-containing amino acid derived from garlic, and dietary inorganic nitrate. Its mechanism of action involves the modulation of the nitric oxide (NO) and hydrogen sulfide (H2S) gasotransmitter pathways. Specifically, it enhances NO bioavailability through the non-canonical nitrate-nitrite-nitric oxide pathway, while SAC serves as a precursor for H2S, which is believed to influence NO biosynthesis and metabolism. Vascanox HP has been evaluated in clinical settings for its efficacy in reducing elevated blood pressure and managing mild-to-moderate hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vascanox HP.